Obesity Masterclass 2026 — Dr. Chetan Kalal, Invited Faculty | MASLD, Metabolic Liver Disease & Bariatric Hepatology

Dr. Chetan Kalal was invited as Faculty to Obesity Masterclass 2026, where he presented on GLP-1 Receptor Agonists in MASH — addressing the role of GLP-1/GIP-based pharmacotherapy at the intersection of obesity and metabolic liver disease — a national masterclass on obesity and metabolic disease management. His faculty slot reflects the critical intersection between hepatology and metabolic medicine: the liver is the primary organ of metabolic dysfunction in obesity, and a DM Hepatologist’s input into obesity management is not peripheral — it is central.

Why a Hepatologist is Essential Faculty at an Obesity Masterclass

Obesity is not primarily a disease of weight — it is a disease of metabolic dysregulation, and the liver is its primary target organ. The spectrum of metabolic-associated steatotic liver disease (MASLD) — formerly NAFLD — runs from simple hepatic steatosis through steatohepatitis (MASH), advanced fibrosis, cirrhosis, and hepatocellular carcinoma. At every stage, the hepatologist’s role is distinct from the bariatric surgeon’s, the endocrinologist’s, or the dietitian’s.

A hepatologist at an obesity masterclass addresses the questions the other specialists cannot:

• When does obesity-related liver disease require liver biopsy — and when is non-invasive fibrosis staging sufficient?
• Which obese patients are already in advanced fibrosis or cirrhosis without knowing it?
• How does bariatric surgery affect the liver — and are there patients for whom bariatric surgery is contraindicated because of liver disease severity?
• What are the emerging pharmacological options for MASH — and what is the evidence threshold for use?
• When does MASLD-related cirrhosis require liver transplant evaluation?

Advisory Panel — Novo Nordisk & Eli Lilly

Dr. Kalal serves on the advisory panels of Novo Nordisk (makers of semaglutide — Ozempic, Wegovy, Rybelsus) and Eli Lilly (makers of tirzepatide — Mounjaro, Zepbound) in the context of GLP-1 and GLP-1/GIP agonist use in metabolic liver disease and obesity. These advisory roles inform his clinical perspective on pharmacotherapy for MASH and allow him to contribute hepatology expertise to the evolving evidence landscape for these agents in liver disease specifically.

Both Novo Nordisk and Eli Lilly have active MASH-specific clinical trial programmes — the ESSENCE trial (semaglutide in MASH cirrhosis) and SYNERGY-NASH (tirzepatide in MASH) respectively. Dr. Kalal’s input as a hepatologist on these panels is directed at refining liver-specific endpoints, patient selection criteria, and the intersection of metabolic pharmacotherapy with advanced liver disease management.

Every obese patient referred for bariatric surgery should have their liver disease stage assessed before the procedure. Advanced fibrosis (F3) or cirrhosis (F4) changes the operative risk profile significantly — and some patients presenting for bariatric surgery already have compensated cirrhosis they were not aware of. The hepatologist’s pre-operative assessment is not optional in these patients; it is a clinical safety requirement.

MASLD — The Liver Disease of the 21st Century

Metabolic-associated steatotic liver disease (MASLD) is now the most prevalent liver disease globally — estimated to affect 25–30% of the general population and 70–80% of obese individuals with type 2 diabetes. In India, MASLD prevalence is approximately 9–32% in the general population and rising sharply with urbanisation, dietary transition, and the epidemic of abdominal obesity and insulin resistance.

The disease trajectory of MASLD:

• Simple steatosis (MASLD without MASH): Excess fat deposition in hepatocytes without significant inflammation. Generally benign natural history — low risk of fibrosis progression. Most obese patients are at this stage.
• MASH (Metabolic-associated steatohepatitis): Steatosis plus hepatocellular injury, inflammation, and ballooning — the histological pattern that drives fibrosis progression. Present in approximately 20–30% of MASLD patients. Annual fibrosis progression rate ~0.07–0.14 stages/year.
• Advanced fibrosis (F3) and cirrhosis (F4): Present in approximately 10–20% of MASH patients. Cirrhosis from MASLD is increasingly the leading indication for liver transplant in Western countries and is rapidly increasing in India.
• HCC on MASLD: Hepatocellular carcinoma can develop even in non-cirrhotic MASLD — a critical distinction from other liver diseases where HCC risk is predominantly in cirrhotic livers. HCC surveillance should not be limited to cirrhotic MASLD patients.

Non-Invasive Assessment of Liver Fibrosis in Obese Patients

Liver biopsy remains the gold standard for fibrosis staging, but it is invasive, costly, and not practical for population-level screening in obese patients. Non-invasive fibrosis assessment tools stratify patients by risk and guide biopsy decisions:

• FIB-4 score (age × AST / (platelets × √ALT)) — the recommended first-line non-invasive tool. FIB-4 <1.30 has high negative predictive value for advanced fibrosis; FIB-4 >2.67 has high positive predictive value. Indeterminate range (1.30–2.67) requires further assessment.
• FibroScan (transient elastography) — liver stiffness measurement (LSM) in kPa. LSM <8 kPa essentially excludes significant fibrosis in MASLD; LSM >12 kPa suggests advanced fibrosis/cirrhosis. Obesity (BMI >35) reduces FibroScan reliability — an M probe or XL probe is required for adequate acquisition in obese patients.
• MRE (magnetic resonance elastography) — more accurate than FibroScan in obese patients; BMI does not affect performance. The gold standard non-invasive tool for fibrosis staging but limited availability and cost.
• VCTE + CAP (controlled attenuation parameter) — simultaneous liver stiffness and hepatic fat quantification on FibroScan. CAP score correlates with hepatic steatosis grade (S0–S3).

The practical algorithm in an obesity clinic: FIB-4 first (calculated from routine bloods). Low FIB-4 = reassurance, lifestyle counselling, repeat in 1–2 years. High FIB-4 = FibroScan + hepatology referral. Indeterminate FIB-4 with metabolic risk factors = FibroScan or direct hepatology referral.

Bariatric Surgery and the Liver — What the Hepatologist Must Know

Bariatric surgery — sleeve gastrectomy, Roux-en-Y gastric bypass (RYGB), and others — has significant hepatic effects, both beneficial and potentially harmful:

Beneficial effects on MASLD

Bariatric surgery produces the most sustained and substantial weight loss currently achievable, and weight loss is the most effective treatment for MASLD. Studies show histological improvement in steatosis, inflammation, and fibrosis after bariatric surgery — including regression of advanced fibrosis in a proportion of patients. Weight loss of >10% body weight consistently improves MASH activity scores.

Hepatic risks of bariatric surgery

• Acute liver failure post-bariatric surgery — rare but reported, particularly in patients with pre-existing advanced fibrosis or cirrhosis. The mechanism includes rapid weight loss-induced lipolysis, altered hepatic blood flow, and nutritional deficiencies (vitamin E, selenium).
• Protein malnutrition — protein restriction post-bariatric surgery in a patient with cirrhosis (who already has impaired protein synthesis and needs adequate dietary protein) can precipitate hepatic decompensation.
• RYGB and altered drug absorption — immunosuppressant absorption is significantly affected by RYGB; relevant for post-transplant patients who subsequently undergo bariatric procedures.

Contraindications from a hepatology perspective

Decompensated cirrhosis (Child-Pugh B or C) is a contraindication to bariatric surgery — operative mortality is prohibitively high. Compensated cirrhosis (Child-Pugh A, MELD <10) can be considered for bariatric surgery at experienced centres with pre-operative hepatology clearance and intraoperative liver biopsy. Portal hypertension (varices, splenomegaly) identified pre-operatively requires endoscopic assessment and variceal management before bariatric surgery is attempted.

Emerging Pharmacotherapy for MASH

2024–2025 has seen the first approvals of MASH-specific pharmacotherapy — a landmark after decades of failed trials:

• Resmetirom (Rezdiffra) — thyroid hormone receptor-β agonist; FDA-approved March 2024 for non-cirrhotic MASH with significant fibrosis (F2–F3). First approved MASH-specific drug. Reduces liver fat and improves MASH activity; fibrosis regression data promising.
• Semaglutide (GLP-1 RA) — robust evidence for weight loss and MASLD improvement; NASH CRN trial showed histological MASH resolution; fibrosis improvement data emerging. Not yet approved specifically for MASH but widely used given the metabolic benefit profile.
• Tirzepatide (GLP-1/GIP dual agonist) — SURMOUNT-1 showed dramatic weight loss; MASLD secondary endpoint data favourable. Phase 3 MASH-specific trials ongoing.
• Lanifibranor, obeticholic acid (second-line) — further options in the pipeline; OCA associated with pruritus and lipid effects limiting its use.

The hepatologist’s role in prescribing for MASH is to ensure fibrosis staging before treatment (so the right drug reaches the right patient), monitor response (with non-invasive tools at 6–12 months), and escalate to transplant evaluation when fibrosis progresses despite treatment.

MASLD and Liver Transplant

MASLD-related cirrhosis is the fastest-growing indication for liver transplant globally. In India, this transition is well underway. The specific challenges in MASLD transplant candidates:

• High prevalence of cardiovascular disease (the leading cause of post-transplant death in MASLD recipients) — mandatory cardiac evaluation before listing
• Obesity itself — BMI >35–40 is a relative contraindication at many centres because of surgical complexity and post-operative wound complications; weight loss before transplant is encouraged where feasible
• Metabolic syndrome recurrence post-transplant — MASLD recurs in the graft in 30–40% of recipients; aggressive metabolic management post-transplant is essential
• Diabetes management — post-transplant diabetes (NODAT) occurs in 20–40% of recipients; MASLD recipients with pre-existing T2DM are at particularly high risk

Dr. Chetan Kalal — Hepatologist at the Metabolic Interface

Dr. Kalal’s invitation as faculty to Obesity Masterclass 2026 reflects his direct clinical experience managing the liver disease end of the obesity-metabolic disease spectrum — from early MASLD detected on routine screening to MASH-related cirrhosis requiring transplant evaluation. At Gleneagles Hospital Mumbai, he works within a multidisciplinary framework alongside bariatric surgeons, endocrinologists, and metabolic medicine specialists.

His research interest in MASLD/metabolic liver disease is documented in his publication record and is a standing strand of his clinical research agenda. The shift from “NAFLD” to “MASLD” nomenclature — formally adopted by international hepatology societies in 2023 — reflects exactly the kind of metabolic framing that positions hepatology within the broader obesity medicine conversation.

Dr. Chetan Kalal is Associate Director, Hepatology & Transplant Medicine, Gleneagles Hospital Mumbai. DM (Hepatology), MD (Medicine), MRCP (UK). First DM Hepatologist of Maharashtra. Faculty at Obesity Masterclass 2026, LTSICON 2026, DRILLS 2026, CRITICON 2026, LIVERCON 2026, and Organising Secretary of Grand Rounds in Hepatology 2026 (INASL Mid-Term). For consultations on MASLD, metabolic liver disease, or cirrhosis: drchetankalal.com/book. Virtual consult for NRI and international patients: drchetankalal.com/virtual-consult.

Frequently Asked Questions

Can obesity cause liver cirrhosis?

Yes. Obesity — particularly abdominal obesity with insulin resistance — causes MASLD, which can progress through MASH to advanced fibrosis and cirrhosis. MASLD-related cirrhosis is now one of the most common indications for liver transplant in India and globally. The progression is slow (years to decades) and often silent — many patients with advanced MASLD-related fibrosis have no symptoms until decompensation.

Does weight loss reverse liver damage from obesity?

Weight loss of 5–7% body weight reduces hepatic steatosis. Weight loss of >10% produces histological improvement in MASH activity. Weight loss of >10–15% can produce fibrosis regression in some patients. Bariatric surgery, producing the most sustained weight loss, shows the strongest evidence for histological improvement — including regression of advanced fibrosis. Cirrhosis itself does not reverse, but its progression can be arrested.

Who is the best MASLD specialist in Mumbai?

Dr. Chetan Kalal — DM (Hepatology), Associate Director at Gleneagles Hospital Mumbai — manages MASLD across the full spectrum: from early-stage steatosis and fibrosis staging to advanced MASLD cirrhosis, HCC surveillance, and transplant evaluation. He has published original research on metabolic liver disease and was invited as faculty to Obesity Masterclass 2026.

Should I see a hepatologist or an endocrinologist for fatty liver disease?

For fatty liver identified on ultrasound with normal LFTs and no metabolic risk factors — a general physician or gastroenterologist can manage initial assessment. For any of the following, hepatology subspecialty referral is appropriate: abnormal LFTs, FIB-4 >1.30, FibroScan showing significant stiffness, suspected MASH, consideration for pharmacotherapy (resmetirom, semaglutide for liver indication), or pre-bariatric surgery liver assessment.

---

Medical disclaimer: This article is for informational and educational purposes only and does not constitute individual clinical advice. For personal assessment of liver disease, book a consultation with Dr. Chetan Kalal. In a liver emergency, attend the nearest emergency department immediately.